Skip to main content
    • Aa
    • Aa
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 40
  • Cited by
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Liao, Zhuangbin Yang, Zhenguo Piontek, Anna Eichner, Miriam Krause, Gerd Li, Longxuan Piontek, Joerg and Zhang, Jingjing 2016. Specific binding of a mutated fragment of Clostridium perfringens enterotoxin to endothelial claudin-5 and its modulation of cerebral vascular permeability. Neuroscience, Vol. 327, p. 53.

    Ono, Yusuke Hiratsuka, Yutaro Murata, Masaki Takasawa, Akira Fukuda, Rieko Nojima, Masanori Tanaka, Satoshi Osanai, Makoto Hirata, Koichi and Sawada, Norimasa 2016. Claudins-4 and -7 might be valuable markers to distinguish hepatocellular carcinoma from cholangiocarcinoma. Virchows Archiv,

    Zimmermann, Arthur 2016. Tumors and Tumor-Like Lesions of the Hepatobiliary Tract.

    Zimmermann, Arthur 2016. Tumors and Tumor-Like Lesions of the Hepatobiliary Tract.

    Erdélyi-Belle, Boglárka Török, György Apáti, Ágota Sarkadi, Balázs Schaff, Zsuzsa Kiss, András and Homolya, László 2015. Expression of Tight Junction Components in Hepatocyte-Like Cells Differentiated from Human Embryonic Stem Cells. Pathology & Oncology Research, Vol. 21, Issue. 4, p. 1059.

    Ouban, Abderrahman and Ahmed, Atif 2015. Analysis of the Distribution and Expression of Claudin-1 Tight Junction Protein in the Oral Cavity. Applied Immunohistochemistry & Molecular Morphology, Vol. 23, Issue. 6, p. 444.

    Bhavaniprasad, V. Febin Prabhu Dass, J. and Jayanthi, S. 2013. Activation mechanism of claudin-4 by ephrin type-A receptor 2: a molecular dynamics approach. Molecular BioSystems, Vol. 9, Issue. 11, p. 2627.

    El Rebey, Hala S. and Aiad, Hayam A. 2013. Prognostic significance of claudin-1 expression in renal cell carcinoma. Egyptian Journal of Pathology, Vol. 33, Issue. 2, p. 198.

    He, Zhi-Yao Wei, Xia-Wei Luo, Min Luo, Shun-Tao Yang, Yang Yu, Yi-Yi Chen, Yan Ma, Cui-Cui Liang, Xiao Guo, Fu-Chun Ye, Ting-Hong Shi, Hua-Shan Shen, Guo-Bo Wang, Wei Gong, Feng-Ming He, Gu Yang, Li Zhao, Xia Song, Xiang-Rong and Wei, Yu-Quan 2013. Folate-linked lipoplexes for short hairpin RNA targeting claudin-3 delivery in ovarian cancer xenografts. Journal of Controlled Release, Vol. 172, Issue. 3, p. 679.

    Tscheik, Christian Blasig, Ingolf E. and Winkler, Lars 2013. Trends in drug delivery through tissue barriers containing tight junctions. Tissue Barriers, Vol. 1, Issue. 2, p. e24565.

    Lal-Nag, M Battis, M Santin, A D and Morin, P J 2012. Claudin-6: a novel receptor for CPE-mediated cytotoxicity in ovarian cancer. Oncogenesis, Vol. 1, Issue. 11, p. e33.

    Maeda, Toshihiro Murata, Masaki Chiba, Hideki Takasawa, Akira Tanaka, Satoshi Kojima, Takashi Masumori, Naoya Tsukamoto, Taiji and Sawada, Norimasa 2012. Claudin-4-targeted therapy using Clostridium perfringens enterotoxin for prostate cancer. The Prostate, Vol. 72, Issue. 4, p. 351.

    Shang, Xiying Lin, Xinjian Alvarez, Edwin Manorek, Gerald and Howell, Stephen B 2012. Tight Junction Proteins Claudin-3 and Claudin-4 Control Tumor Growth and Metastases. Neoplasia, Vol. 14, Issue. 10, p. 974.

    Suzuki, Hidehiko Kondoh, Masuo Takahashi, Azusa and Yagi, Kiyohito 2012. Proof of concept for claudin-targeted drug development. Annals of the New York Academy of Sciences, Vol. 1258, Issue. 1, p. 65.

    Takahashi, Azusa Saito, Yumiko Kondoh, Masuo Matsushita, Kyohei Krug, Susanne M. Suzuki, Hidehiko Tsujino, Hirofumi Li, Xiangru Aoyama, Hiroshi Matsuhisa, Koji Uno, Tadayuki Fromm, Michael Hamakubo, Takao and Yagi, Kiyohito 2012. Creation and biochemical analysis of a broad-specific claudin binder. Biomaterials, Vol. 33, Issue. 12, p. 3464.

    Ushiku, Tetsuo Shinozaki-Ushiku, Aya Maeda, Daichi Morita, Shigeki and Fukayama, Masashi 2012. Distinct expression pattern of claudin-6, a primitive phenotypic tight junction molecule, in germ cell tumours and visceral carcinomas. Histopathology, Vol. 61, Issue. 6, p. 1043.

    Coutinho-Camillo, Cláudia Malheiros Lourenço, Silvia Vanessa Fonseca, Francisco Paulo da and Soares, Fernando Augusto 2011. Claudin expression is dysregulated in prostate adenocarcinomas but does not correlate with main clinicopathological parameters. Pathology, Vol. 43, Issue. 2, p. 143.

    Işeri, Özlem Darcansoy Kars, Meltem Demirel Arpaci, Fikret Atalay, Can Pak, Işin and Gündüz, Ufuk 2011. Drug resistant MCF-7 cells exhibit epithelial-mesenchymal transition gene expression pattern. Biomedicine & Pharmacotherapy, Vol. 65, Issue. 1, p. 40.

    Jang, Kyung-Jun Son, In-seok Shin, Dong Yeok Yoon, Hyun-Min and Choi, Yung Hyun 2011. Anti-invasive Activity of Ethanol Extracts of Ganoderma lucidum through Tightening of Tight Junctions and Inhibition of Matrix Metalloproteinase Activities in Human Gastric Carcinoma Cells. Journal of Acupuncture and Meridian Studies, Vol. 4, Issue. 4, p. 225.

    Kim, Chul Jung Lee, Jeong-Won Choi, Jung-Joo Choi, Hye Young Park, Young-Ae Jeon, Hye-Kyung Sung, Chang Ohk Song, Sang Yong Lee, Yoo-Young Choi, Chel Hun Kim, Tae-Joong Lee, Je-Ho Kim, Byoung-Gie and Bae, Duk-Soo 2011. High claudin-7 expression is associated with a poor response to platinum-based chemotherapy in epithelial ovarian carcinoma. European Journal of Cancer, Vol. 47, Issue. 6, p. 918.


Claudins: emerging targets for cancer therapy

  • Scott L. Kominsky (a1)
  • DOI:
  • Published online: 01 August 2006

The claudin (CLDN) family of transmembrane proteins plays a critical role in the maintenance of epithelial and endothelial tight junctions. In addition to their function in preserving the structure of tight junctions, CLDNs might also play a role in the maintenance of the cytoskeleton and in cell signalling. Interestingly, several studies have recently reported specific CLDN family members to be overexpressed in a wide variety of cancer types. Although their functional role in cancer progression remains unclear, the differential expression of these proteins between tumour and normal cells, in addition to their membrane localisation, makes them prime candidates for cancer therapy. Preclinical studies have shown that tumour cells overexpressing CLDNs can be successfully targeted via several approaches, including the use of anti-CLDN antibodies as well as the cytolytic enterotoxin from Clostridium perfringens. Further studies are needed to determine the potential systemic toxicity of this approach considering the ubiquitous expression of CLDNs in the body, but CLDN-targeted therapeutics appear to have promise in the treatment of cancer.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Expert Reviews in Molecular Medicine
  • ISSN: -
  • EISSN: 1462-3994
  • URL: /core/journals/expert-reviews-in-molecular-medicine
Please enter your name
Please enter a valid email address
Who would you like to send this to? *